Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPX4 | P36969 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | GHSR | Q92847 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3298446 | 1.00 | GPX4 (0.34) | GPX4SLC6A9CYP2D6CYP19A1ALDH1A1 | |
| SCHEMBL4029679 | 0.94 | GPX4 (0.35) | GPX4SLC6A9CYP2D6CYP19A1LMNA | |
| SCHEMBL3297618 | 0.91 | GPX4 (0.34) | GPX4SLC6A9CYP2D6CYP19A1 | |
| SCHEMBL3295171 | 0.88 | HSD17B10 (0.34) | GPX4SLC6A9CYP2D6CYP19A1 | |
| SCHEMBL3304386 | 0.87 | OPRM1 (0.31) | GPX4CYP2D6LMNAADORA3CNR1 | |
| SCHEMBL7653080 | 0.87 | FFAR2 (0.34) | CYP2D6LMNANR1I2ADORA3CNR1 | |
| SCHEMBL7650011 | 0.87 | FFAR2 (0.34) | CYP2D6LMNANR1I2ADORA3CNR1 | |
| SCHEMBL7646797 | 0.86 | CNR1 (0.39) | CNR1 | |
| SCHEMBL6011721 | 0.85 | ACHE (0.40) | CYP2D6NPSR1LMNANR1I2ADORA3 | |
| SCHEMBL3298988 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741316-B2 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2010-06-22 | — | — | US | disclosed |
| US-20050130953-A1 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2005-06-16 | — | — | US | disclosed |
| US-6872717-B2 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20030055033-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ACHARD DANIEL (FR) | 2003-03-20 | — | — | US | disclosed |
| US-6479479-B2 | 1-DIARYLMETHYL-4-ALKYL OR ALKYLSULFONYLALKYL-AZETIDINES; CANNABINOID RECEPTOR ANTAGONISTS; NERVOUS SYSTEM DISORDERS (CNS); CARDIOVASCULAR AND GLANDULAR DISORDERS; DRUG ABUSE; PSYCHOLOGICAL DISORDERS; | AVENTIS PHARMA S.A. (FR) | 2002-11-12 | — | — | US | disclosed |
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2001-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | GPX4 889/4885SLC6A9 1600/4885CYP2D6 7/4885 |
| US-20030055033-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | GPX4 889/4885SLC6A9 1600/4885CYP2D6 7/4885 |
| US-20050130953-A1 | Pharmacological uses of azetidine derivatives | CHRM2, ACHE, DRD2 | GPX4 515/4885SLC6A9 1499/4885CYP2D6 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.